Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: A prospective study

European Radiology

Volumn 23, Issue 7, 2013, Pages 2019-2029

  Bratan, Flavie ^a,b   Niaf, Emilie ^b,g   Melodelima, Christelle ^c   Chesnais, Anne Laure ^d   Souchon, Rémi ^b   Mège Lechevallier, Florence ^d   Colombel, Marc ^d,e,f   Rouvière, Olivier ^a,b,e,f  

^a HOSPICES CIVILS DE LYON   (France)

^b LABTAU   (France)

^c UNIVERSITÉ JOSEPH FOURIER   (France)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e UNIVERSITÉ DE LYON   (France)

^f UNIVERSITÉ LYON 1   (France)

^g UNIVERSITÉ DE LYON   (France)

Author keywords

Gleason score; Magnetic resonance imaging; Prostate cancer; Tumour localisation; Tumour volume

Indexed keywords

ADULT; AGED; AGGRESSIVENESS; ARTICLE; BLEEDING; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER PATIENT; CHRONIC PROSTATITIS; CONTRAST ENHANCEMENT; DIFFUSION WEIGHTED IMAGING; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; RADIOLOGIST;

AGED; BIOPSY; CONTRAST MEDIA; DATABASES, FACTUAL; DIFFUSION MAGNETIC RESONANCE IMAGING; FALSE POSITIVE REACTIONS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; OBSERVER VARIATION; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS;

EID: 84879011392     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-013-2795-0     Document Type: Article

References (50)

1. Lindner U, Trachtenberg J, Lawrentschuk N (2010) Focal therapy in prostate cancer: modalities, findings and future considerations. Nat Rev Urol 7:562-571
2. Rouviere O, Gelet A, Crouzet S, Chapelon JY (2012) Prostate focused ultrasound focal therapy - imaging for the future. Nat Rev Clin Oncol 9:721-727
3. Kirkham AP, Emberton M, Allen C (2006) How good is MRI at detecting and characterising cancer within the prostate? Eur Urol 50:1163-1174, discussion 1175
4. Turkbey B, Pinto PA, Mani H et al (2010) Prostate cancer: value of multiparametric MR imaging at 3T for detection - histopathologic correlation. Radiology 255:89-99
5. Sciarra A, Barentsz J, Bjartell A et al (2011) Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol 59:962-977
6. Riches SF, Payne GS, Morgan VA et al (2009) MRI in the detection of prostate cancer: combined apparent diffusion coefficient, metabolite ratio, and vascular parameters. AJR Am J Roentgenol 193:1583-1591
7. Heidenreich A (2011) Consensus criteria for the use of magnetic resonance imaging in the diagnosis and staging of prostate cancer: not ready for routine use. Eur Urol 59:495-497
8. Girouin N, Mege-Lechevallier F, Tonina Senes A et al (2007) Prostate dynamic contrast-enhanced MRI with simple visual diagnostic criteria: is it reasonable? Eur Radiol 17:1498-1509
9. Cheikh AB, Girouin N, Colombel M et al (2009) Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer before repeat biopsy. Eur Radiol 19:770-778
10. Turkbey B, Mani H, Shah V et al (2011) Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. J Urol 186:1818-1824
11. Rosenkrantz AB, Mendrinos S, Babb JS, Taneja SS (2012) Prostate cancer foci detected on multiparametric magnetic resonance imaging are histologically distinct from those not detected. J Urol 187:2032-2038
12. Isebaert S, Van den Bergh L, Haustermans K et al (2012) Multiparametric MRI for prostate cancer localization in correlation to whole-mount histopathology. J Magn Reson Imaging. doi: 10.1002/jmri.23938
13. Villers A, Puech P, Mouton D, Leroy X, Ballereau C, Lemaitre L (2006) Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. J Urol 176:2432-2437
14. Langer DL, van der Kwast TH, Evans AJ et al (2008) Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2-sparse versus dense cancers. Radiology 249:900-908
15. Tan CH, Wang J, Kundra V (2011) Diffusion weighted imaging in prostate cancer. Eur Radiol 21:593-603
16. Kayhan A, Fan X, Oommen J, Oto A (2010) Multi-parametric MR imaging of transition zone prostate cancer: imaging features, detection and staging. World J Radiol 2:180-187
17. Heijmink SW, Futterer JJ, Hambrock T et al (2007) Prostate cancer: body-array versus endorectal coil MR imaging at 3T - comparison of image quality, localization, and staging performance. Radiology 244:184-195
18. Barentsz JO, Richenberg J, Clements R et al (2012) ESUR prostate MR guidelines 2012. Eur Radiol 22:746-757
19. Kim CK, Park BK, Kim B (2010) Diffusion-weighted MRI at 3T for the evaluation of prostate cancer. AJR Am J Roentgenol 194:1461-1469
20. Dickinson L, Ahmed HU, Allen C et al (2011) Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol 59:477-494
21. Rouviere O, Hartman RP, Lyonnet D (2006) Prostate MR imaging at high-field strength: evolution or revolution? Eur Radiol 16:276-284
22. Shukla-Dave A, Hricak H, Eberhardt SC et al (2004) Chronic prostatitis: MR imaging and 1H MR spectroscopic imaging findings - initial observations. Radiology 231:717-724
23. Akin O, Sala E, Moskowitz CS et al (2006) Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. Radiology 239:784-792
24. Lemaitre L, Puech P, Poncelet E et al (2009) Dynamic contrast-enhanced MRI of anterior prostate cancer: morphometric assessment and correlation with radical prostatectomy findings. Eur Radiol 19:470-480
25. Oto A, Kayhan A, Jiang Y et al (2010) Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology 257:715-723
26. Wang L, Mazaheri Y, Zhang J, Ishill NM, Kuroiwa K, Hricak H (2008) Assessment of biologic aggressiveness of prostate cancer: correlation of MR signal intensity with Gleason grade after radical prostatectomy. Radiology 246:168-176
27. Hambrock T, Somford DM, Huisman HJ et al (2011) Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology 259:453-461
28. Giles SL, Morgan VA, Riches SF, Thomas K, Parker C, deSouza NM (2011) Apparent diffusion coefficient as a predictive biomarker of prostate cancer progression: value of fast and slow diffusion components. AJR Am J Roentgenol 196:586-591
29. Woodfield CA, Tung GA, Grand DJ, Pezzullo JA, Machan JT, Renzulli JF 2nd (2010) Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy. AJR Am J Roentgenol 194:W316-W322
30. Verma S, Rajesh A, Morales H et al (2011) Assessment of aggressiveness of prostate cancer: correlation of apparent diffusion coefficient with histologic grade after radical prostatectomy. AJR Am J Roentgenol 196:374-381
31. Oto A, Yang C, Kayhan A et al (2011) Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. AJR Am J Roentgenol 197:1382-1390
32. Turkbey B, Shah VP, Pang Y et al (2011) Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? Radiology 258:488-495
33. Zakian KL, Sircar K, Hricak H et al (2005) Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 234:804-814
34. Crehange G, Parfait S, Liegard M et al (2011) Tumor volume and metabolism of prostate cancer determined by proton magnetic resonance spectroscopic imaging at 3T without endorectal coil reveal potential clinical implications in the context of radiation oncology. Int J Radiat Oncol Biol Phys 80:1087-1094
35. Chan TY, Partin AW, Walsh PC, Epstein JI (2000) Prognostic significance of Gleason score 3 + 4 versus Gleason score 4 + 3 tumor at radical prostatectomy. Urology 56:823-827
36. Tollefson MK, Leibovich BC, Slezak JM, Zincke H, Blute ML (2006) Long-term prognostic significance of primary Gleason pattern in patients with Gleason score 7 prostate cancer: impact on prostate cancer specific survival. J Urol 175:547-551
37. Noguchi M, Stamey TA, McNeal JE, Yemoto CE (2000) Assessment of morphometric measurements of prostate carcinoma volume. Cancer 89:1056-1064
38. Schned AR, Wheeler KJ, Hodorowski CA et al (1996) Tissue-shrinkage correction factor in the calculation of prostate cancer volume. Am J Surg Pathol 20:1501-1506
39. Stamey TA, McNeal JE, Freiha FS, Redwine E (1988) Morphometric and clinical studies on 68 consecutive radical prostatectomies. J Urol 139:1235-1241
40. Hughes C, Rouviere O, Mege-Lechevallier F, Souchon R, Prost R (2012) Robust alignment of prostate histology slices with quantified accuracy. IEEE Trans Biomed Eng 60:281-291
41. Futterer JJ, Engelbrecht MR, Jager GJ et al (2007) Prostate cancer: comparison of local staging accuracy of pelvic phased-array coil alone versus integrated endorectal-pelvic phased-array coils. Local staging accuracy of prostate cancer using endorectal coil MR imaging. Eur Radiol 17:1055-1065
42. Bloch BN, Rofsky NM, Baroni RH, Marquis RP, Pedrosa I, Lenkinski RE (2004) 3 Tesla magnetic resonance imaging of the prostate with combined pelvic phased-array and endorectal coils; Initial experience(1). Acad Radiol 11:863-867
43. Torricelli P, Cinquantini F, Ligabue G, Bianchi G, Sighinolfi P, Romagnoli R (2006) Comparative evaluation between external phased array coil at 3T and endorectal coil at 1.5T: preliminary results. J Comput Assist Tomogr 30:355-361
44. Beyersdorff D, Taymoorian K, Knosel T et al (2005) MRI of prostate cancer at 1.5 and 3.0T: comparison of image quality in tumor detection and staging. AJR Am J Roentgenol 185:1214-1220
45. Hricak H, White S, Vigneron D et al (1994) Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus integrated endorectal - pelvic phased-array coils. Radiology 193:703-709
46. Ahmed HU, Kirkham A, Arya M et al (2009) Is it time to consider a role for MRI before prostate biopsy? Nat Rev 6:197-206
47. Rouviere O, Papillard M, Girouin N et al (2012) Is it possible to model the risk of malignancy of focal abnormalities found at prostate multiparametric MRI? Eur Radiol 22:1149-1157
48. Scheidler J, Hricak H, Vigneron DB et al (1999) Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging - clinicopathologic study. Radiology 213:473-480
49. Mazaheri Y, Shukla-Dave A, Hricak H et al (2008) Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging - correlation with pathologic findings. Radiology 246:480-488
50. Weinreb JC, Blume JD, Coakley FV et al (2009) Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy-results of ACRIN prospective multi-institutional clinicopathologic study. Radiology 251:122-133